This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Peter Duschet, MD; Thomas Schwarz, MD; Monika Pusch; Agnes Wagner; Fritz Gschnait, MD
Department of Dermatology Vienna Hospital Lainz Wolkersbergenstrasse 1 A-1130 Vienna, Austria

Arch Dermatol. 1987;123(4):428-429.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Anthralin minute entire skin treatment (AMEST) has been developed as a new antipsoriatic regimen¹ to improve the efficacy, practicability, and cosmetic results of anthralin short-contact therapy. Using the dosimetry parameters of AMEST,¹ this treatment has proved a successful and safe outpatient therapy for psoriasis. In our original report, published recently,¹ 43 patients were treated with AMEST and clearing was achieved in 77%, with excellent cosmetic results in most of the patients. Due to the short observation period, however, we were not able to evaluate the duration of the remission phase and the response to a second therapeutic course. In the present study, 131 patients (82 women and 49 men; age, 48 ± 16 years; duration of psoriasis, 16 ± 13 years; and skin pigmentation: type I/II, 79 patients; type III/IV, 52 patients) were allocated to AMEST therapy, and the therapeutic results yielded by AMEST . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?